Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 679-689

  Zhang, Yuhua ^a,b   Wang, Huaiping ^c   Wei, Lijing ^d   Li, Guang ^b   Yu, Jin ^b   Gao, Yan ^e   Gao, Peng ^a   Zhang, Xiaofang ^a   Wei, Fulan ^a   Yin, Deling ^f   Zhou, Gengyin ^a  

^a SHANDONG UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^e SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^f East Tennessee State University   (United States)

Author keywords

BCRP; Breast adenocarcinoma; Gene regulation; Multidrug resistance; Promoter; Toremifene

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTRONE; MITOXANTRONE; TOREMIFENE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; MESSENGER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR PROTEIN;

ARTICLE; BCRP GENE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN RESPONSIVE ELEMENT; GENE REPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; TRANSCRIPTION REGULATION; ADENOCARCINOMA; BINDING SITE; BREAST TUMOR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IC 50; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGEN RECEPTOR ALPHA; ESTRONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MITOXANTRONE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 79952118545     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0660-2     Document Type: Article

References (30)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean MA (1998) Human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339 (Pubitemid 28551112)
2. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13 (Pubitemid 29062946)
3. Borst P, Oude Elferink R (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592 (Pubitemid 34800230)
4. Xu J, Liu Y, Yang Y, Bates S, Zhang JT (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279:19781-19789 (Pubitemid 38623417)
5. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520:234-241 (Pubitemid 32868794)
6. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241 (Pubitemid 29418735)
7. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358 (Pubitemid 37487163)
8. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563 (Pubitemid 29428958)
9. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E (2002) Overexpression of wild-Type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035-5040 (Pubitemid 34984431)
10. Volk EL, Schneider E (2003) Wild-Type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543 (Pubitemid 37139875)
11. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H (2006) Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 100:301-308 (Pubitemid 44707924)
12. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT (2004) Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64:1247-1251 (Pubitemid 38235590)
13. Imai Y, Ishikawa E, Asada S, Sugimoto Y (2005) Estrogenmediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65:596-604
14. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527-25534 (Pubitemid 38756812)
15. Xing W, Sairam MR (2001) Characterization of regulatory elements of ovine follicle-stimulating hormone (FSH) receptor gene: the role of E-box in the regulation of ovine FSH receptor expression. Biol Reprod 64:579-589 (Pubitemid 32109747)
16. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE (2001) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171-182 (Pubitemid 32530764)
17. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2). J Cell Sci 113:2011-2021 (Pubitemid 30386505)
18. Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucl Acids Res 29:2905-2919 (Pubitemid 32685217)
19. Sanchez R, Nguyen D, Rocha W, White JH, Mader S (2002) Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24:244-254 (Pubitemid 34248690)
20. Nguyen D, Bail M, Pesant G, Dupont VN, Rouault E, Deschenes J, Rocha W, Melançon G, Steinberg SV, Mader S (2007) Rational design of an estrogen receptor mutant with altered DNA-binding specificity. Nucl Acids Res 35:3465-3477 (Pubitemid 47073607)
21. Kulakosky PC, McCarty MA, Jernigan SC, Risinger KE, Klinge CM (2002) Response element sequence modulates estrogen receptor alpha and beta affinity and activity. J Mol Endocrinol 29:137-152 (Pubitemid 34965752)
22. Carroll JS, Brown M (2006) Estrogen receptor target gene: An evolving concept. Mol Endocrinol 20:1707-1714 (Pubitemid 44148078)
23. Dubik D, Shiu RP (1992) Mechanism of estrogen activation of cmyc oncogene expression. Oncogene 7:1587-1594
24. Weisz A, Rosales R (1990) Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucl Acids Res 18:5097-5106
25. Sugimoto Y, Tsukahara S, ImaiY,Ueda K, Tsuruo T (2003) Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2:105-112
26. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Estrone and 17b-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93:231-235 (Pubitemid 34464356)
27. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070-1081
28. Panasci L, Jean-Claude BJ, Vasilescu D, Mustafa A, Damian S, Damian Z, Georges E, Liu Z, Batist G, Leyland-Jones B (1996) Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol 52: 1097-1102 (Pubitemid 26338268)
29. Claudio JA, Emerman JT (1996) The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells. Breast Cancer Res Treat 41:111-122 (Pubitemid 26360140)
30. Gruol DJ, Bourgeois S (1997) Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res 57:720-727 (Pubitemid 27085657)